Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The FDA utility for patritumab deruxtecan in handled EGFR-mutant lung most cancers was withdrawn after confirmatory trial knowledge missed survival objectives.The biologics license...
Earlier than the introduction of minimally invasive approaches, resembling EsoGuard, used to display for Barrett’s esophagus, endoscopy was the one possibility for sufferers...
